Studies by Elke et al. [31] and Latini et al. [32] have emphasized MR-proADM’s superior prognostic value compared to traditional biomarkers like NT-proBNP, hs-CRP and PCT, particularly in predicting 30-day mortality in septic and heart failure patients. This evidence concerns the gene NPPB and heart failure.